Grace Therapeutics

GRCE · Nasdaq · United States

Share price · GRCE

$1.73-0.40 (-18.78%) 3M

close as of 2026-11-18 · 24h delayed · vol 28K (0.3x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when GRCE's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 28 Oct 2026+7.5%

    Nothing announced by GRCE that day or the session before.

  2. 26 Oct 2026-6.2%

    Nothing announced by GRCE that day or the session before.

  3. 14 Oct 2026-5.0%

    Nothing announced by GRCE that day or the session before.

  4. 10 Sep 2026+5.6%

    Nothing announced by GRCE that day or the session before.

  5. 23 Apr 2026-45.5%
  6. 14 Apr 2026+12.0%

    Nothing announced by GRCE that day or the session before.

  7. 7 Apr 2026-18.2%

    Nothing announced by GRCE that day or the session before.

  8. 6 Apr 2026-20.7%

    Nothing announced by GRCE that day or the session before.

  9. 30 Mar 2026-6.6%

    Nothing announced by GRCE that day or the session before.

  10. 17 Feb 2026+9.1%

    Nothing announced by GRCE that day or the session before.

Share of unusual movement by asset

For each asset, the share of GRCE's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Nimodipine (GTx-104)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—19%
Other company news (earnings, financing, releases naming no asset)—11%
Sessions with no dated event—70%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
L-type calcium channels (Cav1.2)Small molecule
Subarachnoid Hemorrhage

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

23 April 2026Complete response letterNimodipine (GTx-104)FDA issues complete response letter for the GTx-104 NDA
US, FDA · Grace Therapeutics · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$0.9M$21M$2.1M-$1.8M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$0.7M$14M$16M-$3.2M operating cash flowreport ↗
2025-Q4—$0.5M$19M$2.3M-$2.2M operating cash flowreport ↗
2025-Q3—$0.6M$17M$0.9M-$3.1M operating cash flowreport ↗
2025-Q2—$1.0M$20M$3.4M-$1.8M operating cash flowreport ↗
2024-Q4—$2.2M$11M$4.2M-$4.1M operating cash flowreport ↗
2024-Q3—$3.0M$15M+ <$0.1M short-term inv.$3.4M-$4.2M operating cash flowreport ↗
2024-Q2—$2.7M$19M+ <$0.1M short-term inv.$2.6M-$3.6M operating cash flowreport ↗
2023-Q4—$1.4M$19M+ $6.6M short-term inv.$2.4M-$1.9M operating cash flowreport ↗
2023-Q3—$0.5M$27M+ <$0.1M short-term inv.$3.3M-$2.1M operating cash flowreport ↗
2023-Q2—$1.1M$22M+ <$0.1M short-term inv.$4.0M-$6.2M operating cash flowreport ↗
2022-Q4—$2.5M$26M+ $5.0M short-term inv.$3.9M-$3.7M operating cash flowreport ↗
2022-Q3—$3.3M$35M+ <$0.1M short-term inv.$4.9M-$3.4M operating cash flowreport ↗
2022-Q2—$2.6M$38M+ <$0.1M short-term inv.$4.5M-$5.4M operating cash flowreport ↗
2021-Q4$0$2.2M$33M+ $13M short-term inv.$3.8M-$4.6M operating cash flowreport ↗
2021-Q3—$0.6M$37M+ $14M short-term inv.—-$6.1M operating cash flowreport ↗

Annual history (6 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-FY—$2.4M$17M$1.9M-$8.9M operating cash flowreport ↗

Grace Therapeutics reported R&D spend of $2.4M, down 74.8% YoY, cash and equivalents of $16.98M, and a net loss of $7.79M for fiscal year 2026.

Figures only: this period's report disclosed no narrative text

View 5 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$9.5M$22M$2.4M-$15M operating cash flowreport ↗
2024-FY—$4.7M$23M+ $0 short-term inv.$3.2M-$12M operating cash flowreport ↗
2023-FY—$10.0M$28M+ <$0.1M short-term inv.$11M-$16M operating cash flowreport ↗
2022-FY$0$5.6M$30M+ $13M short-term inv.$2.5M-$17M operating cash flowreport ↗
2021-FY$0.2M$4.2M$51M+ $9.8M short-term inv.$4.9M-$14M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 27 purchases ($923K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-18Opaleye Management Inc. · 10% ownerOpen-market purchase2,974$1.73$5KForm 4
2026-11-17Opaleye Management Inc. · 10% ownerOpen-market purchase29,207$1.72$50KForm 4
2026-11-16Opaleye Management Inc. · 10% ownerOpen-market purchase15,879$1.76$28KForm 4
2026-11-05Opaleye Management Inc. · 10% ownerOpen-market purchase3,087$1.77$5KForm 4
2026-11-04Opaleye Management Inc. · 10% ownerOpen-market purchase5,027$1.80$9KForm 4
2026-11-03Opaleye Management Inc. · 10% ownerOpen-market purchase10,328$1.79$18KForm 4
2026-10-26Opaleye Management Inc. · 10% ownerOpen-market purchase66,411$1.77$117KForm 4
2026-10-22Opaleye Management Inc. · 10% ownerOpen-market purchase21,390$1.93$41KForm 4